Supplementary Figure 11: Cleavage of masked ADCs in vivo.
From: A coiled-coil masking domain for selective activation of therapeutic antibodies
Western blot analysis of tumor, plasma, and liver samples from an HPAF-II xenograft tumor model. Mice bearing HPAF-II tumors (100 mm3) were dosed with 3 mg/kg of CC2B-h15H3-gluc-MMAE(8) ADCs bearing either cleavable (PLGLAG) or scrambled (LALGPG) cleavage sequences, or the h15H3-gluc-MMAE(8) parent ADC. At 4 days post-dose, mice were sacrificed and tissues were harvested. Antibody was purified from homogenized tissue samples using protein A capture and the presence of intact or cleaved antibody was assessed via western blot. The experiment was conducted once with n = 3 mice for CC2B-PLGLAG-h15H3, n = 2 mice for CC2B-LALGPG-h15H3, and n = 3 mice for h15H3.
